Inflammatory bowel disease – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 11:25:00 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Inflammatory bowel disease – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Modafinil for Severe Fatigue in Patients with Quiescent Inflammatory Bowel Disease https://clinicaltrials.eu/trial/a-study-to-evaluate-the-use-of-modafinil-for-treating-severe-fatigue-in-patients-with-inactive-inflammatory-bowel-disease/ Thu, 07 May 2026 05:47:16 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-use-of-modafinil-for-treating-severe-fatigue-in-patients-with-inactive-inflammatory-bowel-disease/ This clinical trial is studying inflammatory bowel disease, a long-term condition that causes swelling and irritation in the gut, and fatigue, which means severe tiredness that does not improve with rest. The treatment being tested is modafinil, taken by mouth as a tablet, compared with placebo. The purpose of the study is to see whether modafinil can help reduce severe fatigue in people whose inflammatory bowel disease is not active.

People taking part will receive study tablets over a period of several weeks. During the study, there will be follow-up visits at different times so that changes in tiredness and general well-being can be checked, and safety will also be monitored. Some people will receive modafinil and some will receive placebo, but the treatment is assigned by chance.

]]> Study Using Fluorescent Adalimumab and Risankizumab to See How These Drugs Work in Patients with Inflammatory Bowel Disease https://clinicaltrials.eu/trial/study-using-fluorescent-adalimumab-and-risankizumab-to-see-how-these-drugs-work-in-patients-with-inflammatory-bowel-disease/ Wed, 29 Apr 2026 15:08:04 +0000 https://clinicaltrials.eu/trial/study-using-fluorescent-adalimumab-and-risankizumab-to-see-how-these-drugs-work-in-patients-with-inflammatory-bowel-disease/ This study is looking at Inflammatory Bowel Disease, which is a condition where the digestive tract becomes inflamed and causes symptoms like abdominal pain and diarrhea. The study will use two medications that are already approved for treating this condition: adalimumab and risankizumab. These medications will be modified by attaching special fluorescent dyes to them, which means they will glow under certain types of light. The adalimumab will be labeled with a dye called IRDye 680LT, and the risankizumab will be labeled with IRDye 800CW. The purpose of this study is to test whether a special imaging system called the Windu system can detect and see both of these glowing medications at the same time during an endoscopy, which is a procedure where a flexible tube with a camera is used to look inside the digestive tract.

During the study, patients who have active Inflammatory Bowel Disease and are eligible to receive either adalimumab or risankizumab as part of their treatment will undergo an endoscopy procedure. The fluorescently labeled medications will be given to patients before the endoscopy, and doctors will use special cameras and imaging equipment to see where these medications go in the digestive tract. The cameras can detect the glow from the dyes attached to the medications, allowing doctors to see exactly where the drugs are reaching in the inflamed areas. During the endoscopy, small tissue samples called biopsies will be taken from areas that show high and low amounts of glowing signal. These tissue samples will be examined in the laboratory using various techniques to measure how much of the medication is present and to understand how the medication is distributed in inflamed versus non-inflamed tissue.

The study will analyze the fluorescent signals both during the endoscopy procedure and afterward in the laboratory. Researchers will measure the strength of the glowing signals and compare them with how severe the inflammation is in different areas of the digestive tract. The tissue samples will be studied using microscopy and other laboratory methods to see which types of immune cells have taken up the medications and to measure the levels of specific proteins and genetic material related to inflammation. The study aims to understand whether this imaging technique can help visualize how these medications reach their targets in the body and whether the amount of fluorescent signal relates to the severity of inflammation and the response to treatment.

]]> Study on How Gut Bacteria Affect Energy Use in Cells for Healthy Adults and Patients with Inflammatory Bowel Disease Using Amphotericin B, Vancomycin, and Gentamicin Sulfate https://clinicaltrials.eu/trial/study-on-how-gut-bacteria-affect-energy-use-in-cells-for-healthy-adults-and-patients-with-inflammatory-bowel-disease-using-amphotericin-b-vancomycin-and-gentamicin-sulfate/ Wed, 29 Apr 2026 15:05:54 +0000 https://clinicaltrials.eu/trial/study-on-how-gut-bacteria-affect-energy-use-in-cells-for-healthy-adults-and-patients-with-inflammatory-bowel-disease-using-amphotericin-b-vancomycin-and-gentamicin-sulfate/ This clinical trial is focused on understanding the impact of the gut microbiota on energy metabolism in people with and without Inflammatory Bowel Disease (IBD). The study involves healthy adults and patients with IBD who are in remission. IBD is a condition that causes inflammation in the digestive tract, and it includes diseases like Crohn’s Disease and ulcerative colitis. The purpose of the study is to evaluate how changes in the gut microbiota affect the energy metabolism of immune cells in the body.

Participants in the study will receive different treatments, including Gentamicin, Amphotericin B, and Vancomycin. These are antibiotics that help fight infections. The study will also involve the use of a placebo. Over the course of the study, participants will take these medications orally for a period of up to seven days. The study will also involve taking blood samples to assess the energy metabolism of immune cells and using a special technique to track how the body processes certain nutrients.

The study aims to provide insights into how the gut microbiota and its changes in IBD affect the body’s energy use. This could help improve understanding of IBD and lead to better treatments in the future. Participants will be monitored throughout the study to ensure their safety and to gather important data on how their bodies respond to the treatments.

]]> Study on Pain Relief Using Lidocaine and Sodium Chloride in Patients with Chronic Inflammatory Bowel Disease and Abdominal Pain https://clinicaltrials.eu/trial/study-on-pain-relief-using-lidocaine-and-sodium-chloride-in-patients-with-chronic-inflammatory-bowel-disease-and-abdominal-pain/ Wed, 29 Apr 2026 15:05:21 +0000 https://clinicaltrials.eu/trial/study-on-pain-relief-using-lidocaine-and-sodium-chloride-in-patients-with-chronic-inflammatory-bowel-disease-and-abdominal-pain/ This clinical trial is focused on patients with chronic inflammatory bowel disease (IBD), which includes conditions like Crohn’s disease and ulcerative colitis. These conditions often cause abdominal pain, which can significantly affect daily life. The study is investigating the effects of a treatment using lidocaine hydrochloride monohydrate, a medication commonly used for its pain-relieving properties. The treatment will be administered as an infusion, which means it will be given directly into the bloodstream through a vein.

The purpose of the study is to see if this treatment can reduce pain intensity by at least 50% in patients with IBD. The study will also explore how the treatment affects brain connectivity, which refers to how different parts of the brain communicate with each other. This will be compared between patients with IBD and healthy volunteers who do not have the disease. The study will involve two phases: the first phase will focus on pain reduction, and the second phase will examine changes in brain connectivity.

Participants will receive either the lidocaine infusion or a placebo and will be monitored to assess changes in their pain levels and brain activity. The goal is to reduce the background pain scores and decrease the frequency of hyperalgesia flare-ups, which are episodes of increased sensitivity to pain. By doing so, the study aims to lessen the psychosocial impacts associated with chronic pain in these patients. The trial is expected to provide valuable insights into the potential benefits of lidocaine for managing pain in IBD patients.

]]> Title: Study of vedolizumab dose adjustment guided by drug level monitoring in patients with inflammatory bowel disease in remission https://clinicaltrials.eu/trial/study-on-reducing-vedolizumab-dosage-using-drug-monitoring-for-patients-with-inflammatory-bowel-disease-in-remission/ Wed, 29 Apr 2026 15:03:38 +0000 https://clinicaltrials.eu/trial/study-on-reducing-vedolizumab-dosage-using-drug-monitoring-for-patients-with-inflammatory-bowel-disease-in-remission/ This study focuses on patients with Inflammatory Bowel Disease, a condition that causes inflammation in the digestive tract. The study will examine whether adjusting the dose of vedolizumab, a medication that helps control inflammation, can be done more efficiently by monitoring drug levels in the blood while maintaining the same treatment benefits.

The research involves patients who have either Crohn’s Disease or Ulcerative Colitis (two types of inflammatory bowel disease) whose condition is currently stable. The medication used in this study, Entyvio, is given as an injection under the skin (subcutaneous injection). The study will compare two different approaches to giving the medication: the standard way of giving fixed doses versus adjusting the dose based on measuring drug levels in the blood.

The study will last for 48 weeks, during which participants will receive injections of the medication. The main goal is to determine if adjusting the medication dose based on blood levels can be more cost-effective than the standard dosing approach while maintaining the same treatment benefits for patients.

]]> Study on the Safety of Faster Infusions for Cancer Patients Using Trastuzumab, Bevacizumab, and Atezolizumab https://clinicaltrials.eu/trial/study-on-the-safety-of-faster-infusions-for-cancer-patients-using-trastuzumab-bevacizumab-and-atezolizumab/ Wed, 29 Apr 2026 15:01:58 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-faster-infusions-for-cancer-patients-using-trastuzumab-bevacizumab-and-atezolizumab/ This clinical trial is focused on studying the safety of shortened infusion times for various cancer treatments known as monoclonal antibodies. These treatments include nivolumab, pembrolizumab, ipilimumab, bevacizumab, trastuzumab, durvalumab, atezolizumab, and rituximab. Monoclonal antibodies are a type of protein made in the lab that can bind to substances in the body, including cancer cells. The purpose of the study is to determine how often and how severe infusion-related reactions occur when these medications are given more quickly than usual.

Participants in the study will receive one of the mentioned treatments through an intravenous infusion, which means the medication is delivered directly into a vein. The study will observe and record any reactions that occur during these faster infusions. These reactions can include symptoms like fever, chills, or rash, which are sometimes experienced when the body responds to the medication. The study will compare these reactions to those recorded in past treatments where the infusions were given at a standard pace.

The study will continue over a period of time, with participants receiving their treatments and being monitored for any side effects. The goal is to gather information on whether these faster infusions are safe and to understand the experiences of patients undergoing these treatments. This information could help improve the way these cancer therapies are administered in the future, potentially making them more convenient for patients. The study will also look at other factors such as the effectiveness of the treatment and the overall experience of the patients involved.

]]> Study Comparing Infliximab Alone or with Immunosuppressive Drugs for Moderate to Severe Crohn’s Disease Patients https://clinicaltrials.eu/trial/study-comparing-infliximab-alone-or-with-immunosuppressive-drugs-for-moderate-to-severe-crohns-disease-patients/ Wed, 29 Apr 2026 14:59:49 +0000 https://clinicaltrials.eu/trial/study-comparing-infliximab-alone-or-with-immunosuppressive-drugs-for-moderate-to-severe-crohns-disease-patients/ This clinical trial is focused on studying the treatment of Crohn’s disease, a condition that causes inflammation in the digestive tract, leading to symptoms like abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. The study is investigating the effectiveness of a medication called infliximab, which is administered as a solution for injection using a pre-filled pen. Infliximab is a type of protein that helps reduce inflammation in the body.

The purpose of this study is to compare two treatment approaches for moderate to severe Crohn’s disease: using infliximab injections alone or in combination with other drugs that suppress the immune system, known as immunosuppressive drugs. Participants in the study will receive either infliximab alone or infliximab with these additional medications. The study aims to determine which approach is more effective in managing the disease.

Throughout the study, participants will receive regular injections and will be monitored over a period of time to assess their response to the treatment. The goal is to see if patients can achieve a state where they no longer need corticosteroids, a type of medication often used to reduce inflammation, and to observe improvements in their digestive tract as seen through medical examinations. The study will last until the end of 2025, with participants being observed for changes in their condition and overall health.

]]> Study on the Safety and Imaging of Risankizumab-800CW for Patients with Inflammatory Bowel Disease https://clinicaltrials.eu/trial/study-on-the-safety-and-imaging-of-risankizumab-800cw-for-patients-with-inflammatory-bowel-disease/ Wed, 29 Apr 2026 14:59:48 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-imaging-of-risankizumab-800cw-for-patients-with-inflammatory-bowel-disease/ This clinical trial is focused on studying Inflammatory Bowel Disease (IBD), which includes conditions like Crohn’s disease and ulcerative colitis. The study will use a treatment called risankizumab-800CW, a special form of the medication risankizumab, which is designed to help visualize how the drug targets the disease in the body. Risankizumab is a type of protein used to treat inflammation in the bowel. The purpose of the study is to evaluate the safety and effectiveness of this treatment in patients with IBD.

Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor the safety of the treatment by checking vital signs and observing any reactions at the injection site. Additionally, the study will use a technique called fluorescence molecular endoscopy (FME) to detect signals from the treatment, helping researchers determine the best dose for imaging. This involves using a special camera to see how the drug interacts with the body.

The study will also involve taking tissue samples to analyze the presence of the drug and its effects on the bowel. This will help researchers understand how the drug is distributed in inflamed and non-inflamed tissues. The study aims to find a correlation between the drug’s presence and the level of inflammation, providing insights into how well the treatment works in targeting the disease. The trial is expected to continue until October 2025.

]]> Study on Subcutaneous Infliximab for Patients with Ulcerative Colitis, Crohn’s Disease, or Unclassified Inflammatory Bowel Disease https://clinicaltrials.eu/trial/study-on-subcutaneous-infliximab-for-patients-with-ulcerative-colitis-crohns-disease-or-unclassified-inflammatory-bowel-disease/ Wed, 29 Apr 2026 14:30:19 +0000 https://clinicaltrials.eu/trial/study-on-subcutaneous-infliximab-for-patients-with-ulcerative-colitis-crohns-disease-or-unclassified-inflammatory-bowel-disease/ This clinical trial is focused on studying the effects of a medication called infliximab on patients with certain types of inflammatory bowel diseases, including Ulcerative Colitis, Crohn’s Disease, and Inflammatory Bowel Disease Unclassified. The study involves switching patients from an intravenous (IV) form of infliximab, which is administered directly into a vein, to a subcutaneous (SC) form, which is injected under the skin. The purpose of the study is to compare the outcomes of patients receiving subcutaneous infliximab every week with those receiving it every other week, after they have been stabilized on an optimized intravenous schedule.

Participants in the study will have previously been in a state of remission, meaning their disease symptoms were under control, without the use of steroids. The study will observe patients over a period of time to see if they can maintain this remission while using the subcutaneous form of infliximab. The trial will last up to 52 weeks, during which the health and experiences of the participants will be monitored to assess the effectiveness and safety of the subcutaneous treatment.

The study will also look at how many patients remain in remission without needing to adjust their treatment, as well as how many might need to switch back to the intravenous form of infliximab. Additionally, the trial will gather information on patients’ satisfaction with the subcutaneous treatment and any side effects they may experience. This research aims to provide valuable insights into the management of these chronic conditions and potentially offer a more convenient treatment option for patients.

]]> Study on the Safety and Imaging of Adalimumab-680LT for Patients with Inflammatory Bowel Disease https://clinicaltrials.eu/trial/study-on-the-safety-and-imaging-of-adalimumab-680lt-for-patients-with-inflammatory-bowel-disease/ Wed, 29 Apr 2026 14:25:28 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-imaging-of-adalimumab-680lt-for-patients-with-inflammatory-bowel-disease/ This clinical trial is focused on studying Inflammatory Bowel Disease (IBD), which includes conditions like Crohn’s disease and ulcerative colitis. The treatment being investigated is a medication called Adalimumab-680LT, which is a version of the drug Humira. This study aims to explore the safety and effectiveness of using a special form of Adalimumab that is labeled with a fluorescent dye to help visualize how the drug targets the disease in the body.

The purpose of the study is to evaluate the safety of Adalimumab-680LT by monitoring participants’ vital signs and checking for any adverse reactions after the drug is administered. Additionally, the study will investigate how well a technique called fluorescence molecular endoscopy can detect the drug in the body. This involves using a special camera to see the fluorescent signals from the drug, which helps determine the best dose for imaging purposes.

Participants in the study will receive injections of Adalimumab-680LT and will undergo various imaging procedures to observe how the drug behaves in the body. The study will also compare images and tissue samples taken before and after at least 14 weeks of treatment to understand how the drug affects inflamed and non-inflamed tissues. This research will provide insights into the presence of immune cells and the stability of the drug within the body, contributing to a better understanding of its potential benefits for treating IBD.

]]> Study on the Effectiveness of Infliximab for Children with Inflammatory Bowel Disease https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-infliximab-for-children-with-inflammatory-bowel-disease/ Wed, 29 Apr 2026 14:23:06 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-infliximab-for-children-with-inflammatory-bowel-disease/ This clinical trial is focused on studying the effects of a medication called Infliximab on children and adolescents with Inflammatory Bowel Disease (IBD). Inflammatory Bowel Disease is a condition that causes inflammation in the digestive tract, leading to symptoms like stomach pain, diarrhea, and weight loss. The study aims to understand how well Infliximab works and how long its effects last when used early in treatment.

Participants in the study will receive Infliximab, which is given as a solution through an infusion, meaning it is administered directly into the bloodstream. The study will compare two different approaches to using Infliximab: one group will receive the medication according to a standard schedule, while the other group will have their treatment adjusted based on regular monitoring of the drug levels in their blood. This approach is known as proactive therapeutic drug monitoring.

The study will last for about a year, during which time researchers will observe how the treatment affects the participants’ health. They will look at factors such as whether the medication needs to be stopped due to side effects or if the treatment needs to be intensified because it is not working as expected. The goal is to find out if adjusting the treatment based on drug levels can improve the effectiveness and durability of Infliximab in treating IBD in young patients.

]]>